Acceleron Pharma’s investigational treatment for pulmonary arterial hypertension showed positive outcomes in a mid-stage trial, the company announced on Monday.

The treatment, sotatercept, showed significant reduction in pulmonary vascular resistance versus placebo at week 24.

It also showed significant improvements in patients functional capacity, which was determined by a six minute walk test.